New Commissioning Policy: Fluticasone furoate and vilanterol trifenatate (Relvar® Ellipta®) combination inhaler for asthma

The routine commissioning of Relvar® Ellipta® combination inhaler is accepted in Devon for the regular treatment of asthma in adults and adolescents aged 12 years and older. Formulary Interface Groups should include this in locally defined treatment recommendations.

The full policy can be accessed here

 

Home > Referral > Key messages > Key Messages Archive > New Commissioning Policy: Fluticasone furoate and vilanterol trifenatate (Relvar® Ellipta®) combination inhaler for asthma

 

  • First line
  • Second line
  • Specialist
  • Hospital